Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment, inability to perform activities of daily living and mood changes. Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in neurodegenerative conditions, including AD. However, it is not clear that the purported effectiveness of statins in neurodegenerative disorders is directly related to cholesterol-lowering effects of these agents; rather, the pleiotropic functions of statins likely play critical roles. The aim of this review is to provide an overview on the new discoveries about the effects of statin therapy on the oxidative ad nitrosative stress levels as well as on the modulation of the heme oxygenase/biliverdin reductase (HO/BVR) system in the brain. We propose a novel mechanism of action for atorvastatin which, through the activation of HO/BVR-A system, may contribute to the neuroprotective effects thus suggesting a potential therapeutic role in AD and potentially accounting for the observation of decreased AD incidence with persons on statin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543 · cited 1×
“NO plays a key role in the long-term potentiation and synaptic plasticity [110].”
BackgroundSelf-citationEvidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Self-citationMetabolism and function of coenzyme Q
Turunen, M., Olsson, J., & Dallner, G. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2003.11.012 · Cited by 1,026
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808 · cited 1×
“About 30 cases of serious hepatic failure and 42 cases of death due to rhabdomyolisis associated with statin administration were reported to the FDA over the last 15 years [13,14].”
BackgroundVassar, R., Kovacs, D. M., Yan, R., & Wong, P. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3657-09.2009 · Cited by 577
Butterfield, D. A., Reed, T., Newman, S. F., & Sultana, R. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.037 · Cited by 564
Self-citationRandomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
How does PKMζ maintain long-term memory?
Sacktor, T. C. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2949 · Cited by 431
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 4×
“[29] found that statins (atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin”
BackgroundResultInfluentialDepletion of GGA3 Stabilizes BACE and Enhances β-Secretase Activity
Tesco, G., Koh, Y. H., Kang, E. L., Cameron, A. N., Das, S., Sena-Esteves, M., Hiltunen, M., Yang, S.-H., Zhong, Z., Shen, Y., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.012 · Cited by 337
Antioxidant and prooxidant properties of mitochondrial Coenzyme Q
James, A. M., Smith, R. A. J., & Murphy, M. P. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.12.025 · Cited by 292
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291 · cited 6×
“Elderly at Risk (PROSPER) [40,41] included 5804 patients ranging in age from 70 to 82 years with mean follow-up of 3.”
BackgroundInfluentialOxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
Functions of coenzyme Q10 in inflammation and gene expression
Schmelzer, C., Lindner, I., Rimbach, G., Niklowitz, P., Menke, T., & Döring, F. (2008) · BioFactors · doi:10.1002/biof.5520320121 · Cited by 265
Upregulation of CREB-Mediated Transcription Enhances Both Short- and Long-Term Memory
Suzuki, A., Fukushima, H., Mukawa, T., Toyoda, H., Wu, L.-J., Zhao, M.-G., Xu, H., Shang, Y., Endoh, K., Iwamoto, T., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3257-10.2011 · Cited by 250
Perluigi, M., Coccia, R., & Butterfield, D. A. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4406 · Cited by 229 · cited 1×
“Also the association statins and fibrates should be avoided, in particular gemfibrozil [13].”
BackgroundCoenzyme Q10 and statins: Biochemical and clinical implications
Littarru, G. P., & Langsjoen, P. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.002 · Cited by 188 · cited 1×
“Coversely, the neurotoxic effects include: (i) increased cell death [53]; (ii) decreased CoQ10 levels [54,55]; (iii) inhibition of Ras-induced ERK1/2 phosphorylation”
BackgroundBarone, E., Di Domenico, F., Mancuso, C., & Butterfield, D. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.018 · Cited by 127
Self-citationTong, X.-K., Nicolakakis, N., Fernandes, P., Ongali, B., Brouillette, J., Quirion, R., & Hamel, E. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.003 · Cited by 122
Kurata, T., Miyazaki, K., Kozuki, M., Panin, V.-L., Morimoto, N., Ohta, Y., Nagai, M., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.067 · Cited by 98
Butterfield, D. A., Barone, E., & Mancuso, C. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.007 · Cited by 80 · cited 4×
“Our group was the first to propose BVR-A as a novel drug-target for atorvastatin in the brain [7,143].”
BackgroundInfluentialSelf-citationBarone, E., Mancuso, C., Di Domenico, F., Sultana, R., Murphy, M. P., Head, E., & Butterfield, D. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07538.x · Cited by 75
Self-citation
Cited by
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Role of natural products for the treatment of Alzheimer’s disease
Noori, T., Dehpour, A. R., Sureda, A., Sobarzo-Sanchez, E., & Shirooie, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173974 · Cited by 141
HSV-1 and Alzheimer’s disease: more than a hypothesis
Piacentini, R., De Chiara, G., Li Puma, D. D., Ripoli, C., Marcocci, M. E., Garaci, E., Palamara, A. T., & Grassi, C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00097 · Cited by 130
“Among the proposed pharmacological treatments for AD, the use of statins seems to be promising (Barone et al., 2013).”
BackgroundButterfield, D. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.006 · Cited by 126
Self-citationWang, S., Zhang, X., Zhai, L., Sheng, X., Zheng, W., Chu, H., & Zhang, G. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1032-3 · Cited by 52
Metadata
- Authors
- Barone, E., Di Domenico, F., & Butterfield, D. A.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 88
- Issue
- 4
- Pages
- 605-616
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2076948181
- Cited by
- 79
- References
- 25
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.